Krystal Biotech, Inc. key statistics and ratios

In fiscal 2025, Krystal Biotech, Inc. had return on equity of 18.9%, an operating margin of 41.5%, debt equal to 0.0% of equity and a current ratio of 9.95. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Krystal Biotech, Inc.: financial ratios, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Operating margin	—	—	−216.2%	22.6%	41.5%	48.4%
Net margin	—	—	21.6%	30.7%	52.6%	47.9%
Free-cash-flow margin	—	—	−198.4%	41.0%	48.5%	66.0%
Return on equity	−11.7%	−25.1%	1.7%	10.3%	18.9%	17.0%
Return on assets	−11.1%	−23.6%	1.6%	9.5%	17.1%	15.4%
Asset turnover	—	—	0.07	0.31	0.33	0.32
Current ratio	17.18	13.30	17.76	7.28	9.95	7.89
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	n/m	—	—	—	—	—
Effective tax rate	—	—	15.2%	6.5%	−8.1%	13.0%
R&D as % of revenue	—	—	91.6%	18.4%	14.9%	12.7%
SG&A as % of revenue	—	—	193.9%	39.1%	37.7%	33.2%
Capital spending as % of revenue	—	—	23.3%	1.5%	3.1%	2.9%
Free cash flow ÷ net income	—	—	−920.3%	133.7%	92.2%	137.7%

US$ thousands unless shown otherwise. Fiscal quarters.

Krystal Biotech, Inc.: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Operating margin	45.4%	41.1%	41.0%	42.3%	41.3%	46.1%	49.0%	55.9%
Net margin	49.9%	40.5%	39.9%	81.2%	48.0%	48.1%	45.9%	49.5%
Free-cash-flow margin	57.1%	28.1%	52.9%	38.8%	70.4%	62.9%	59.7%	70.9%
Current ratio	7.28	9.65	9.68	10.14	9.95	9.46	8.32	7.89
R&D as % of revenue	14.8%	16.2%	15.0%	14.9%	13.8%	13.2%	12.2%	11.7%
SG&A as % of revenue	34.3%	37.0%	36.5%	38.4%	38.7%	35.2%	33.4%	26.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · September 30, 2026

What it owns · $1.6bn

Short-term assets $1.1bnLonger-term assets $464m

What it owes, and who funded it · $1.6bn

Short-term liabilities $142mLonger-term liabilities $8mShareholders' equity $1.4bn

Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $142m of liabilities due within a year.
Short-term assets cover long-term liabilities $1.1bn short-term assets against $8m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Krystal Biotech, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ARQT vs KRYS CRMD vs KRYS ARDX vs KRYS ADMA vs KRYS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Krystal Biotech, Inc.